Antibody-drug conjugates: Principles and opportunities

Antibody–drug conjugates (ADCs) are immunoconjugates that combine the specificity of monoclonal antibodies with a cytotoxic agent. The most appealing aspects of ADCs include their potential additive or synergistic effects of the innate backbone antibody and cytotoxic effects of the payload on tumors...

Full description

Saved in:
Bibliographic Details
Published in:Life sciences (1973) 2024-06, Vol.347, p.122676-122676, Article 122676
Main Authors: Phuna, Zhi Xin, Kumar, Prashanth Ashok, Haroun, Elio, Dutta, Dibyendu, Lim, Seah H.
Format: Article
Language:English
Subjects:
Antibody-drug conjugates
Backbone antibodies
Linkers
Payloads
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Antibody–drug conjugates (ADCs) are immunoconjugates that combine the specificity of monoclonal antibodies with a cytotoxic agent. The most appealing aspects of ADCs include their potential additive or synergistic effects of the innate backbone antibody and cytotoxic effects of the payload on tumors without the severe toxic side effects often associated with traditional chemotherapy. Recent advances in identifying new targets with tumor-specific expression, along with improved bioactive payloads and novel linkers, have significantly expanded the scope and optimism for ADCs in cancer therapeutics. In this paper, we will first provide a brief overview of antibody specificity and the structure of ADCs. Next, we will discuss the mechanisms of action and the development of resistance to ADCs. Finally, we will explore opportunities for enhancing ADC efficacy, overcoming drug resistance, and offer future perspectives on leveraging ADCs to improve the outcome of ADC therapy for cancer treatment. [Display omitted]
ISSN:0024-3205
1879-0631
DOI:10.1016/j.lfs.2024.122676